Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen

Shuji Shirakawa, executive managing director at the National Federation of Health Insurance Societies ( Kenporen ) and a representative of bill payers at the Central Social Insurance Medical Council (CSIMC; Chuikyo ), offered his thoughts on FY2012 NHI pricing reform...read more